Novartis: positive data in hidrosadenitis suppurativa
(CercleFinance.com) - In a late-breaking presentation at the 31st Congress of the European Academy of Dermatology and Venereology (EADV), Novartis announced positive results from two pivotal Phase III studies (SUNSHINE and SUNRISE) with its Cosentyx.
The product demonstrated superior efficacy compared to placebo, with a statistically significant improvement in common clinical signs and symptoms of moderate-to-severe hidrosadenitis suppurativa, with a favorable safety profile.
Data from these trials have been submitted to health authorities in Europe and are expected to be submitted in the US by the end of the year. A chronic, inflammatory skin condition, hidrosadenitis suppurativa affects up to 1% of people worldwide.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The product demonstrated superior efficacy compared to placebo, with a statistically significant improvement in common clinical signs and symptoms of moderate-to-severe hidrosadenitis suppurativa, with a favorable safety profile.
Data from these trials have been submitted to health authorities in Europe and are expected to be submitted in the US by the end of the year. A chronic, inflammatory skin condition, hidrosadenitis suppurativa affects up to 1% of people worldwide.
Copyright (c) 2022 CercleFinance.com. All rights reserved.